Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials

BACKGROUND: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease (CD) in the main trial displayed a close to significant difference favouring...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BioDrugs
Autori principali: Jørgensen, Kristin K., Goll, Guro L., Sexton, Joe, Bolstad, Nils, Olsen, Inge C., Asak, Øivind, Berset, Ingrid P., Blomgren, Ingrid M., Dvergsnes, Katrine, Florholmen, Jon, Frigstad, Svein O., Henriksen, Magne, Hagfors, Jon, Huppertz-Hauss, Gert, Haavardsholm, Espen A., Klaasen, Rolf A., Moum, Bjørn, Noraberg, Geir, Prestegård, Ulf, Rydning, Jan H., Sagatun, Liv, Seeberg, Kathrine A., Torp, Roald, Vold, Cecilia, Warren, David J., Ystrøm, Carl M., Lundin, Knut E. A., Kvien, Tore, Jahnsen, Jørgen
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2020
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7519917/
https://ncbi.nlm.nih.gov/pubmed/32965617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-020-00438-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi